First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay -- ...
First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback